HLB bioStep Co.,Ltd. (KOSDAQ:278650)
1,781.00
-51.00 (-2.78%)
At close: Mar 28, 2025, 3:30 PM KST
HLB bioStep Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Operating Revenue | 58,169 | 52,814 | 86,277 | 64,403 | 58,520 | Upgrade
|
Other Revenue | - | - | - | 0 | - | Upgrade
|
Revenue | 58,169 | 52,814 | 86,277 | 64,403 | 58,520 | Upgrade
|
Revenue Growth (YoY) | 10.14% | -38.78% | 33.96% | 10.05% | 27.11% | Upgrade
|
Cost of Revenue | 17,339 | 17,533 | 32,343 | 23,147 | 15,819 | Upgrade
|
Gross Profit | 40,830 | 35,281 | 53,934 | 41,256 | 42,701 | Upgrade
|
Selling, General & Admin | 46,407 | 31,623 | 40,986 | 26,527 | 29,515 | Upgrade
|
Research & Development | 824.35 | 811.99 | 978.14 | 1,165 | 1,085 | Upgrade
|
Other Operating Expenses | 858.76 | 712.99 | 709.09 | 696.32 | 500.65 | Upgrade
|
Operating Expenses | 53,877 | 36,467 | 48,625 | 32,249 | 35,662 | Upgrade
|
Operating Income | -13,048 | -1,186 | 5,309 | 9,007 | 7,040 | Upgrade
|
Interest Expense | -858.96 | -3,471 | -4,246 | -184.7 | -202.22 | Upgrade
|
Interest & Investment Income | 1,821 | 1,469 | 1,401 | 85 | 205.4 | Upgrade
|
Earnings From Equity Investments | 1.68 | -488.74 | -1,659 | 3,608 | -56.87 | Upgrade
|
Currency Exchange Gain (Loss) | 4.16 | 32.3 | 13.81 | 9.9 | -6.45 | Upgrade
|
Other Non Operating Income (Expenses) | 233.81 | 561.71 | -2,767 | 775.48 | 235.87 | Upgrade
|
EBT Excluding Unusual Items | -11,845 | -3,083 | -1,947 | 13,300 | 7,215 | Upgrade
|
Gain (Loss) on Sale of Investments | 182.73 | 3,418 | 534.22 | -440.56 | 2,259 | Upgrade
|
Gain (Loss) on Sale of Assets | 135.08 | -9.47 | -23.37 | -33.11 | -3.31 | Upgrade
|
Asset Writedown | - | - | -907.99 | - | - | Upgrade
|
Pretax Income | -11,528 | 325.66 | -2,345 | 12,827 | 9,471 | Upgrade
|
Income Tax Expense | -1,835 | 379.9 | -1,462 | 1,295 | 881.82 | Upgrade
|
Earnings From Continuing Operations | -9,693 | -54.24 | -882.73 | 11,532 | 8,589 | Upgrade
|
Net Income to Company | -9,693 | -54.24 | -882.73 | 11,532 | 8,589 | Upgrade
|
Minority Interest in Earnings | 1,128 | -109.81 | -125.27 | -501.4 | -287.6 | Upgrade
|
Net Income | -8,564 | -164.04 | -1,008 | 11,031 | 8,302 | Upgrade
|
Net Income to Common | -8,564 | -164.04 | -1,008 | 11,031 | 8,302 | Upgrade
|
Net Income Growth | - | - | - | 32.87% | 97.88% | Upgrade
|
Shares Outstanding (Basic) | 86 | 82 | 70 | 68 | 67 | Upgrade
|
Shares Outstanding (Diluted) | 86 | 82 | 70 | 70 | 69 | Upgrade
|
Shares Change (YoY) | 4.42% | 17.17% | 0.02% | 1.35% | 13.51% | Upgrade
|
EPS (Basic) | -100.00 | -2.00 | -14.40 | 161.87 | 123.76 | Upgrade
|
EPS (Diluted) | -100.00 | -2.00 | -14.40 | 158.00 | 120.22 | Upgrade
|
EPS Growth | - | - | - | 31.42% | 74.23% | Upgrade
|
Free Cash Flow | -20,594 | 1,189 | 1,587 | -11,135 | 7,517 | Upgrade
|
Free Cash Flow Per Share | -240.46 | 14.50 | 22.67 | -159.09 | 108.85 | Upgrade
|
Gross Margin | 70.19% | 66.80% | 62.51% | 64.06% | 72.97% | Upgrade
|
Operating Margin | -22.43% | -2.25% | 6.15% | 13.98% | 12.03% | Upgrade
|
Profit Margin | -14.72% | -0.31% | -1.17% | 17.13% | 14.19% | Upgrade
|
Free Cash Flow Margin | -35.40% | 2.25% | 1.84% | -17.29% | 12.85% | Upgrade
|
EBITDA | -8,345 | 2,290 | 9,412 | 12,033 | 9,095 | Upgrade
|
EBITDA Margin | -14.35% | 4.33% | 10.91% | 18.68% | 15.54% | Upgrade
|
D&A For EBITDA | 4,703 | 3,476 | 4,103 | 3,026 | 2,056 | Upgrade
|
EBIT | -13,048 | -1,186 | 5,309 | 9,007 | 7,040 | Upgrade
|
EBIT Margin | -22.43% | -2.25% | 6.15% | 13.98% | 12.03% | Upgrade
|
Effective Tax Rate | - | 116.66% | - | 10.09% | 9.31% | Upgrade
|
Advertising Expenses | 178.58 | 152.13 | 340.63 | 256.01 | 126.79 | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.